Antabio is a clinical-stage biopharmaceutical company based in Labège, France, led by CEO and founder Marc Lemonnier. It develops novel and highly differentiated antibacterial treatments addressing CDC/WHO critical priority drug-resistant pathogens, with particular emphasis on life‑threatening respiratory infections and hospital-acquired infections. Its lead program, MEM-ANT3310, is a next‑generation antibacterial combination currently in Phase 1 trials being developed for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). The company’s pipeline also includes ANT3273, an inhalation treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary disease patients, and ANT2681, a metallo beta‑lactamase (MBL) inhibitor intended to be combined with meropenem for MBL-producing CRE, including NDM strains. Antabio plans to use the recent financing to support the clinical development of MEM-ANT3310. Antabio is a private biopharmaceutical company founded in 2009 in Labège, France, focused on developing novel antibacterial resistance-breakers for high unmet medical needs. Its core programs include a metallo ß-lactamase inhibitor to be combined with a carbapenem for nosocomial infections and a first-in-class inhibitor of Pseudomonas virulence (PEi) for chronic respiratory infections. The PEi program is being developed as an inhaled adjunct to standard-of-care antibiotics targeting the LasB elastase to reduce tissue damage, inflammation, and pathogen persistence in cystic fibrosis lungs. The company has received Wellcome Trust Seeding Drug Discovery Awards for two programs, supporting its preclinical efforts. Antabio aims to advance its PEi candidate through non-GLP preclinical studies and toward clinical development as a means to enhance existing antibiotic effectiveness for CF patients. The firm positions its work against the global antimicrobial-resistance challenge and seeks to deliver innovative, life-saving therapeutic options. Antabio SAS is a Labège, France–based biopharmaceutical company led by CEO Marc Lemonnier that develops novel antibacterial resistance‑breakers for high‑unmet‑need drug‑resistant infections. Its lead program is a novel inhibitor of bacterial metallo ß‑lactamases (MBLs) intended to be combined with a carbapenem to treat nosocomial drug‑resistant infections. A second program is a first‑in‑class inhibitor of Pseudomonas virulence to be co‑administered with standard‑of‑care antibiotics for long‑term management of chronic respiratory infections. Another program, the Pseudomonas Elastase Inhibitor (PEI), has received CARB‑X funding. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards. The company expects its lead product to enter the clinic in 2019 with anticipated fast track approval. The new Series A funding will be used to accelerate development of the MBL inhibitor program.

Total raised

$33M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2023